CN1913917B - 凝血酶肽衍生物的药物组合物 - Google Patents

凝血酶肽衍生物的药物组合物 Download PDF

Info

Publication number
CN1913917B
CN1913917B CN2004800414872A CN200480041487A CN1913917B CN 1913917 B CN1913917 B CN 1913917B CN 2004800414872 A CN2004800414872 A CN 2004800414872A CN 200480041487 A CN200480041487 A CN 200480041487A CN 1913917 B CN1913917 B CN 1913917B
Authority
CN
China
Prior art keywords
gly
pharmaceutical composition
asp
pro
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800414872A
Other languages
English (en)
Chinese (zh)
Other versions
CN1913917A (zh
Inventor
D·W·霍布森
R·S·克劳瑟
D·H·卡尼
A·P·K·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capstone Therapy Co
University of Texas System
Original Assignee
Orthologic Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthologic Corp filed Critical Orthologic Corp
Publication of CN1913917A publication Critical patent/CN1913917A/zh
Application granted granted Critical
Publication of CN1913917B publication Critical patent/CN1913917B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN2004800414872A 2003-12-31 2004-12-30 凝血酶肽衍生物的药物组合物 Expired - Fee Related CN1913917B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53373003P 2003-12-31 2003-12-31
US60/533,730 2003-12-31
PCT/US2004/044012 WO2005065706A1 (en) 2003-12-31 2004-12-30 Pharmaceutical composition for thrombin peptide derivatives

Publications (2)

Publication Number Publication Date
CN1913917A CN1913917A (zh) 2007-02-14
CN1913917B true CN1913917B (zh) 2012-02-01

Family

ID=34652502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800414872A Expired - Fee Related CN1913917B (zh) 2003-12-31 2004-12-30 凝血酶肽衍生物的药物组合物

Country Status (13)

Country Link
US (2) US7291596B2 (https=)
EP (1) EP1559431B1 (https=)
JP (1) JP5044829B2 (https=)
CN (1) CN1913917B (https=)
AT (1) ATE357928T1 (https=)
AU (1) AU2004312090B2 (https=)
CA (1) CA2551525C (https=)
DE (1) DE602004005564T2 (https=)
DK (1) DK1559431T3 (https=)
ES (1) ES2287660T3 (https=)
PL (1) PL1559431T3 (https=)
PT (1) PT1559431E (https=)
WO (1) WO2005065706A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60313982T2 (de) * 2002-07-02 2008-01-17 Orthologic Corp., Tempe Dimere von thrombinpeptidderivaten
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
JP2010504336A (ja) * 2006-09-22 2010-02-12 オーソロジック コーポレイション 血管内皮機能不全を治療する方法
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CA2722621A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
US20110105400A1 (en) * 2008-03-26 2011-05-05 Orthologic Corp. Methods for treating acute myocardial infarction
EP2280722A2 (en) * 2008-03-26 2011-02-09 Orthologic Corp. Method of treating degenerative diseases
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2011106222A2 (en) 2010-02-23 2011-09-01 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
US10124066B2 (en) * 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
BR112016007382B1 (pt) * 2013-10-03 2021-12-21 Luis Alberto Améstica Salazar Composição biocida de resinas que compreendem uma ou mais resinas selecionadas de resinas mf, uf, pf, muf e fenólicas; e mais de um sal de cobre solúvel
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CN105879010A (zh) * 2015-01-17 2016-08-24 内蒙古天奇生物科技有限公司 一种能促进创伤愈合减轻创后瘢痕的多肽组合物及其制备方法
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
EP3952991A4 (en) * 2019-04-12 2023-08-09 Affirmed Pharma, LLC RUSALATIDE ACETATE COMPOSITIONS
JP2023139750A (ja) * 2022-03-22 2023-10-04 株式会社東芝 抗酸化剤を用いたｆｅｔセンサ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409334A (en) * 1980-05-22 1983-10-11 Boehringer Mannheim Gmbh Stabilized thrombin preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
JP2000229882A (ja) * 1998-12-10 2000-08-22 Sankyo Co Ltd 修飾シクロデキストリン含有トロンビン水性液剤
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
ATE254925T1 (de) * 2000-07-19 2003-12-15 Univ Texas Stimulierung des knochenwachstums mit peptidderivaten von thrombin
AU7356101A (en) * 2000-07-20 2002-02-05 Univ Texas Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
AU2002223802A1 (en) * 2000-11-17 2002-05-27 Warner-Lambert Company Llc Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
WO2002074806A2 (en) * 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
ES2271216T3 (es) 2001-07-27 2007-04-16 Orthologic Corp. Uso de los peptidos derivados de la trombina para la terapia de las ulceras dermicas cronicas.
ATE504311T1 (de) 2002-01-16 2011-04-15 Capstone Therapeutics Corp Thrombin-derivierten peptiden zur förderung von herzgewebsreparatur
JP2005519067A (ja) 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
WO2003092731A1 (en) * 2002-05-03 2003-11-13 Novo Nordisk A/S Stabilised solid compositions of modified factor vii
DE60313982T2 (de) 2002-07-02 2008-01-17 Orthologic Corp., Tempe Dimere von thrombinpeptidderivaten
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409334A (en) * 1980-05-22 1983-10-11 Boehringer Mannheim Gmbh Stabilized thrombin preparation

Also Published As

Publication number Publication date
AU2004312090B2 (en) 2008-08-14
JP5044829B2 (ja) 2012-10-10
CN1913917A (zh) 2007-02-14
EP1559431A1 (en) 2005-08-03
EP1559431B1 (en) 2007-03-28
CA2551525A1 (en) 2005-07-21
PT1559431E (pt) 2007-07-02
AU2004312090A1 (en) 2005-07-21
DE602004005564D1 (de) 2007-05-10
US20050203017A1 (en) 2005-09-15
HK1080390A1 (en) 2006-04-28
WO2005065706A1 (en) 2005-07-21
DE602004005564T2 (de) 2007-12-13
ES2287660T3 (es) 2007-12-16
DK1559431T3 (da) 2007-07-30
JP2007518724A (ja) 2007-07-12
ATE357928T1 (de) 2007-04-15
US7875588B2 (en) 2011-01-25
PL1559431T3 (pl) 2007-10-31
US20090054343A1 (en) 2009-02-26
CA2551525C (en) 2013-02-19
US7291596B2 (en) 2007-11-06

Similar Documents

Publication Publication Date Title
CN1913917B (zh) 凝血酶肽衍生物的药物组合物
US7919457B2 (en) Thrombin peptide derivative dimers
US6855687B2 (en) Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
JP2005053894A (ja) トロンビンペプチド誘導体による骨成長の刺激
US7713934B2 (en) Thrombin peptide derivatives
CN1622826A (zh) 用凝血酶肽衍生物刺激骨生长和软骨形成
HK1080390B (en) Pharmaceutical composition for thrombin peptide derivatives
Ali US PATENT DOCUMENTS
HK1078264A (en) Stimulation of bone growth and cartilage formation with thrombing peptide derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER OWNER: CAPSTONE THERAPEUTICS CORP.

Effective date: 20130826

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: CAPSTONE THERAPEUTICS CORP.

Free format text: FORMER NAME: UNIV TEXAS

CP01 Change in the name or title of a patent holder

Address after: Arizona USA

Patentee after: Capstone therapy Co.

Address before: Arizona USA

Patentee before: ORTHOLOGIC Corp.

TR01 Transfer of patent right

Effective date of registration: 20130826

Address after: Texas in the United States

Patentee after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Address before: Arizona USA

Patentee before: Capstone therapy Co.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120201

Termination date: 20131230